News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Recro Pharma (REPH) Announces Dosing Of First Patient In Phase 2b Clinical Trial Of Dex-IN For Treatment Of Acute Pain Following Surgery


6/17/2014 8:51:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MALVERN, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced dosing of the first patient in a Phase IIb clinical trial of Dex-IN in patients undergoing bunionectomy surgery.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES